DRTS News and Press, Alpha Tau Medical Ltd. From 11/16/23

- Treated the first patient with advanced inoperable pancreatic cancer at Hadassah Medical Center in Israel in September, alongside safety and feasibility trial in similar indication currently underway in Montreal, Canada - - 89% CR, two-year local recurrence-free survival of 77%, and n...

JERUSALEM, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will participate in the following investor co...

2023-10-30 08:45:26 ET More on Alpha Tau Medical Alpha Tau Medical files to sell 1.1M ordinary shares for holders Alpha Tau Medical GAAP EPS of -$0.24, revenue of $12.26M Historical earnings data for Alpha Tau Medical For further details see: Alpha Tau en...

JERUSALEM, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that its U.S. subsidiary, Alpha Tau Medical Inc., has entered...

JERUSALEM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Stephen M. Hahn, M.D., former commissioner of the U.S. F...

JERUSALEM, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that a patient with advanced inoperable pancre...

2023-09-11 16:49:34 ET More on Alpha Tau Medical Seeking Alpha’s Quant Rating on Alpha Tau Medical Historical earnings data for Alpha Tau Medical Financial information for Alpha Tau Medical Alpha Tau Medical GAAP EPS of -$0.24, revenue of $12.26M ...

2023-08-28 16:23:52 ET More on Alpha Tau Medical Alpha Tau gains on data for radiation therapy Alpha Tau Medical a new buy at HC Wainwright on proprietary radiation therapy Alpha Tau director gives up board seat to take up chief commercial officer role Israel...

– Treated the first patient with advanced inoperable pancreatic cancer in a safety and feasibility trial in Canada in April – – 89% CR , two-year local recurrence-free survival of 77% , and no treatment-related grade 2 or higher late-onset toxicity ...

JERUSALEM, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will participate in the following investor conferences. ...